Compugen Ltd. (NASDAQ:CGEN) Shares Acquired by Northern Trust Corp

Northern Trust Corp increased its stake in shares of Compugen Ltd. (NASDAQ:CGEN - Free Report) by 936.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 941,825 shares of the biotechnology company's stock after buying an additional 850,997 shares during the period. Northern Trust Corp owned about 1.06% of Compugen worth $1,441,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC purchased a new stake in Compugen during the fourth quarter worth about $32,000. Oppenheimer & Co. Inc. boosted its holdings in Compugen by 187.3% during the fourth quarter. Oppenheimer & Co. Inc. now owns 55,602 shares of the biotechnology company's stock worth $85,000 after buying an additional 36,252 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Compugen during the fourth quarter worth about $103,000. Marshall Wace LLP boosted its holdings in Compugen by 84.9% during the fourth quarter. Marshall Wace LLP now owns 88,169 shares of the biotechnology company's stock worth $135,000 after buying an additional 40,494 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Compugen by 15.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 317,500 shares of the biotechnology company's stock worth $486,000 after buying an additional 43,165 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company's stock.

Compugen Price Performance

Shares of NASDAQ CGEN traded down $0.04 on Friday, hitting $1.49. The company's stock had a trading volume of 77,662 shares, compared to its average volume of 366,084. Compugen Ltd. has a 12-month low of $1.13 and a 12-month high of $2.66. The company has a market capitalization of $132.96 million, a price-to-earnings ratio of 74.50 and a beta of 2.61. The stock has a 50 day moving average of $1.39 and a 200-day moving average of $1.67.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings results on Monday, May 19th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The business had revenue of $2.28 million during the quarter, compared to analysts' expectations of $3.70 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%. During the same period last year, the company earned ($0.08) EPS. Sell-side analysts expect that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded shares of Compugen from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.